Possible Autoimmune Primary Ovarian Insufficiency in Patients with Selective IgA Deficiency

Eli Magen MD1,2,3, Atheer Masalha MD3,4, Ekaterina Zueva MD PhD2 and Daniel A. Vardy MD MSc3,4

1Leumit Health Services, Ashkelon, Israel
2Department of Medicine C, Allergy and Clinical Immunology Unit, Barzilai Medical Center, Ashkelon, Israel
3Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
4Department of Dermatology, Soroka Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel

KEY WORDS: selective IgA deficiency (sIgAD), autoimmune, primary ovarian insufficiency (POI)

S

elective IgA deficiency (sIgAD) is one of the most common form of primary immunodeficiency in the Western world. In 85–90% of the cases, individuals with sIgAD are asymptomatic; however, autoimmune diseases are some of the most important clinical manifestations in sIgAD, especially in females [1]. In this case report, we discuss the unusual association of sIgAD and autoimmune primary ovarian insufficiency (POI) in three patients.

PATIENT DESCRIPTION

Three patients were chosen from our cohort of 347 subjects (aged 12–74 years). These three women had been diagnosed with sIgAD based on the codes of International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM). The women were enrolled in the Leumit Healthcare Services health fund in Israel and had been referred to outpatient fertility clinics with amenorrhea and desired fertility.

The nulligravida patients had no history of chemotherapy or radiotherapy (Karyotype 46, XX). All three had normal growth and sexual development. Their mean age was 26.3 ± 2.5 years (range 24–29). The hormonal screening showed the presence of increased follicle-stimulating hormone (FSH) and luteinizing hormone (LH) associated with low levels of estradiol and molecular studies ruled out Fragile X syndrome and mutated FSH receptor gene. Molecular studies to rule out Fragile X syndrome are the routine test in infertility workup. Prolactin, testosterone, and cortisol serum levels were normal. Although TSH levels were also in the normal range, two patients had positive antithyroid antibodies. A transvaginal and pelvic ultrasound did not show any abnormality. None of the patients had any systemic and/or organ specific autoimmune disorders. Anti- adrenal (anti-21-hydroxylase antibodies) and steroid cell autoantibodies tested by immunofluorescence were negative (other anti-ovarian antibodies were not checked). None of these patients had undergone an ovarian biopsy.

COMMENT

POI is defined as sustained amenorrhea before the age of 40 years. FSH levels greater than 40 IU/L, and estrogen levels generally lower than 50 pg/ml are associated with infertility [2]. Approximately 1% of women are affected by POI and the etiology is multifactorial, including single gene mutations, autoimmune diseases, and metabolic infectious and iatrogenic factors. Of women with POI, 5% are believed to have autoimmune POI [2]. There are three different forms of autoimmune POI: associated with adrenal autoimmunity, associated with non-adrenal autoimmunity, and idiopathic POI [3]. With autoimmune POI cases, 60–80% are associated with autoimmune Addison disease in the setting of autoimmune polyendocrine syndromes: type I (autoimmune polyendocrinopathy candidiasis ectodermal dystrophy) and type II (polygenic syndrome with autoimmune Addison disease and other autoimmune diseases without hypoparathyroidism) [2,3]. Autoimmune POI can be diagnosed with characteristic histological inflammatory features in ovary biopsy and circulating ovarian and/or adrenal autoantibodies [3]. The most sensitive indicators of adrenal autoimmunity are adenocortical antibodies and 21-hydroxylase enzyme antibodies; whereas, steroid cell antibodies and ovarian enzyme antibodies (antibodies to cytochrome P450 side-chain cleavage enzyme and antibodies to 17-α hydroxylase/17,20-lyase enzyme) identify ovarian autoimmunity [4]. Autoimmune POI can arise about 8–14 years before the onset of adrenal insufficiency, and autoantibodies to the adrenal gland may not be positive at the time of the initial POI diagnosis [3]. However, absence of serum anti-adrenal and/or anti-ovary autoantibodies do not exclude an autoimmune etiology POI [5]. Most probably, in patients with autoimmune POI, a combination of cell-mediated and humoral immunity play a role in ovarian autoimmunity [5].

The association between POI and numerous systemic and organ-specific autoimmune diseases were documented for many years and its prevalence varies from 10–20% to 55% [3]. According the diagnostic criteria of autoimmune POI/ diminished ovarian reserve (DOR), all three
Table 1. Summary of three cases with primary ovarian insufficiency and selective IgA deficiency

<table>
<thead>
<tr>
<th>Case</th>
<th>Body mass index</th>
<th>Age at POI onset</th>
<th>Age at menarche</th>
<th>Karyotype</th>
<th>FMR1 gene analysis</th>
<th>Early menopause in a first-degree relative</th>
<th>Personal history of autoimmunity</th>
<th>Pregnancy history</th>
<th>Pelvic ultrasonography</th>
<th>Pregnancy history of autoimmunity</th>
<th>Anti-thyroglobulin Ab</th>
<th>Anti-thyroperoxidase Ab</th>
<th>Anti-nuclear Ab</th>
<th>Anti-thyroglobulin Ab</th>
<th>Serum inhibin B (pg/ml)</th>
<th>Serum LH at initial diagnosis (mIU/ml)</th>
<th>Serum LH at initial diagnosis (mlU/ml)²</th>
<th>Serum FSH at initial diagnosis (mIU/ml)²</th>
<th>Serum LH range</th>
<th>Serum FSH range</th>
<th>Anti-mullerian hormone (ng/ml)</th>
<th>Anti-mullerian hormone (ng/ml)³</th>
<th>Anti-mullerian hormone (ng/ml)⁴</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>27.1</td>
<td>24</td>
<td>12</td>
<td>46, XX</td>
<td>No mutation</td>
<td>No</td>
<td>Negative</td>
<td>G</td>
<td>Normal</td>
<td>Autoimmune disease</td>
<td>Positive</td>
<td>Negative</td>
<td>Negative</td>
<td>Positive</td>
<td>24</td>
<td>14</td>
<td>158.3</td>
<td>62.5</td>
<td>0.4</td>
<td>4.7-21.5</td>
<td>0.4-105 mlU/ml</td>
<td>0.4</td>
<td>0.4</td>
</tr>
<tr>
<td>2</td>
<td>26.9</td>
<td>26</td>
<td>11</td>
<td>46, XX</td>
<td>No mutation</td>
<td>No</td>
<td>Negative</td>
<td>G</td>
<td>Normal</td>
<td>Autoimmune disease</td>
<td>Negative</td>
<td>Positive</td>
<td>Negative</td>
<td>Positive</td>
<td>63</td>
<td>9</td>
<td>94.1</td>
<td>85.8</td>
<td>85.8</td>
<td>4.7-21.5</td>
<td>0.4-105 mlU/ml</td>
<td>0.4</td>
<td>0.4</td>
</tr>
<tr>
<td>3</td>
<td>25.2</td>
<td>29</td>
<td>12</td>
<td>46, XX</td>
<td>No mutation</td>
<td>No</td>
<td>Negative</td>
<td>Autoimmune disease</td>
<td>Autoimmune disease</td>
<td>Positive</td>
<td>Positive</td>
<td>Positive</td>
<td>Positive</td>
<td>1</td>
<td>11</td>
<td>129.8</td>
<td>54.1</td>
<td>54.1</td>
<td>0.4-105 mlU/ml</td>
<td>0.4-105 mlU/ml</td>
<td>1.1</td>
<td>1.1</td>
<td></td>
</tr>
</tbody>
</table>

POI = primary ovarian insufficiency, FMR1 = fragile X mental retardation 1, FSH = follicle-stimulating hormone, LH = luteinizing hormone

1 Serum E2 range ≤ 10–80 pg/ml
2 Serum FSH range 4.7–21.5 mIU/ml
3 Serum LH range ≤ 0.4-105 mlU/ml
4 Serum inhibin B (Serotec, Oxford, UK, range 15–160 pg/ml)
5 Serum alpha macrofetoprotein (Immunotech, Beckman-Coulter, range 0.4-21 ng/ml), ab-antibodies

of these cases might be defined as possible POI/DOR.

CONCLUSIONS

Based on our observations, we conclude that POI may be one of the concomitant autoimmune diseases in sIgAD.

Correspondence

Dr. E. Magen
Dept. of Medicine C, Allergy and Clinical Immunology Unit, Barzilai Medical Center, Ashkelon 87306, Israel
Phone: (972-8) 674-5710
Fax: (972-8) 674-5285
email: allergology.com@gmail.com

References


Capsule

Self-acupressure for older adults with symptomatic knee osteoarthritis: a randomized controlled trial

In a double-blind randomized controlled trial, Li et al. aimed to test the efficacy of self-administered acupressure for pain and physical function improvement for older adults with knee osteoarthritis (OA). Participants were community-dwelling adults with symptomatic knee OA (n=150, mean age 73 years), randomized to 1 of 3 groups: verum acupressure, sham acupressure, or usual care. Participants in the verum and sham groups, but not those in the usual care group, were taught to self-apply acupressure once daily, 5 days/week for 8 weeks. Compared with usual care, both verum and sham acupressure participants experienced significant improvements in WOMAC pain (mean difference: -1.27 units, 95% confidence interval [95%CI] -1.95, -0.58; and -1.24 units, 95%CI -1.92, -0.55, respectively), NRS pain (-0.74 units, 95%CI -1.24, -0.24 and -0.51 units, 95%CI -1.01, -0.01, respectively), and WOMAC function (+4.83 units, 95%CI -6.99, -2.67 and -4.21 units, 95%CI -6.37, -2.04, respectively) at 8 weeks. There were no significant differences between the verum and sham acupressure groups on any of the outcomes. Self-administered acupressure is superior to usual care in pain and physical function improvement for older adults with knee OA. The reason for the benefits is unclear, and the placebo effect may play a role.

Li et al.

Arthritis Care Res 2018; 70: 221
Eitan Israeli

“Life is mostly froth and bubble / Two things stand like stone / Kindness in another’s trouble / Courage in your own”

Adam Lindsay Gordon, (1833–1870), Australian police officer, poet, jockey and politician